Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

United Therapeutics (UTHR) Receivables (2016 - 2026)

United Therapeutics' Receivables history spans 17 years, with the latest figure at $350.2 million for Q4 2025.

  • On a quarterly basis, Receivables rose 25.38% to $350.2 million in Q4 2025 year-over-year; TTM through Dec 2025 was $350.2 million, a 25.38% increase, with the full-year FY2025 number at $350.2 million, up 25.38% from a year prior.
  • Receivables hit $350.2 million in Q4 2025 for United Therapeutics, up from $297.7 million in the prior quarter.
  • Over the last five years, Receivables for UTHR hit a ceiling of $379.3 million in Q2 2025 and a floor of $134.5 million in Q1 2023.
  • Historically, Receivables has averaged $251.8 million across 5 years, with a median of $265.6 million in 2023.
  • Biggest five-year swings in Receivables: decreased 21.11% in 2023 and later surged 128.48% in 2024.
  • Tracing UTHR's Receivables over 5 years: stood at $198.7 million in 2021, then rose by 10.92% to $220.4 million in 2022, then increased by 26.54% to $278.9 million in 2023, then rose by 0.14% to $279.3 million in 2024, then grew by 25.38% to $350.2 million in 2025.
  • Business Quant data shows Receivables for UTHR at $350.2 million in Q4 2025, $297.7 million in Q3 2025, and $379.3 million in Q2 2025.